title: Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics.
abstract: OBJECTIVE
  We evaluated prevalence and risk factors for metabolic syndrome in inpatients treated with antipsychotics, with or without other psychotropic drugs. Although the literature on metabolic syndrome in psychiatry has expanded in recent years, we seek to elucidate some of the remaining gaps by examining a severely and chronically ill population heavily treated with pharmacological agents.
  
  
  METHODS
  With data from medical records of 589 adults hospitalized at McLean Hospital in 2010 and 2011, we used standard statistical analyses to characterize risks and covariates of metabolic syndrome.
  
  
  RESULTS
  With prior antipsychotic treatment, prevalence of metabolic syndrome was 29.5%. The syndrome was strongly associated with being overweight (≥25 kg/m(2) in 60.1% of subjects), older age, longer treatment-exposure, schizoaffective diagnosis (39.8%), more illness-episodes or hospitalizations, polytherapy, and higher total daily chlorpromazine-equivalent doses, but not sex. Notably, metabolic syndrome risk was greater among young, antipsychotic treated patients (15.5-fold at age ≤25 years).
  
  
  CONCLUSIONS
  The findings extend information on the association of metabolic syndrome with antipsychotic treatment. Metabolic syndrome was found in 30% of antipsychotic-exposed inpatients. Risk was surprisingly high in young persons and after brief treatment-exposure, and psychotropic polytherapy increased risk.
authors.affiliation: Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA. fcentorrino@partners.org
authors.forename: Franca
authors.initials: F
authors.lastname: Centorrino
authors.forename: Grace A
authors.initials: GA
authors.lastname: Masters
authors.forename: Alessandra
authors.initials: A
authors.lastname: Talamo
authors.forename: Ross J
authors.initials: RJ
authors.lastname: Baldessarini
authors.forename: Dost
authors.initials: D
authors.lastname: Öngür
mesh_terms: D000328:Adult; D000367:Age Factors; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000453:epidemiology; D008875:Middle Aged; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D013997:Time Factors; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D011619:Psychotropic Drugs